Bovine Lactoferrin in the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial

Frontiers in Pediatrics

article

Michal F. Wronowski¹  Maria Kotowska¹  Marcin Banasiuk¹  Artur Kotowski³  Weronika Kuzmicka⁴  Piotr Albrecht¹ 

[1] Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw;Department of Pediatrics With Clinical Assessment Unit, Medical University of Warsaw;Polish Association for Good Clinical Practice;Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw;Postgraduate School of Molecular Medicine, Medical University of Warsaw

关键词: lactoferrin;    antibiotic-associated diarrhea;    children;    Clostridioides difficile;    probiotics;   

DOI  :  10.3389/fped.2021.675606

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Introduction: Antibiotic-associated diarrhea (AAD) is a common adverse reaction to antibiotic treatment affecting up to 21% of children. The aim of the study is to evaluate whether bovine lactoferrin (bLf) might be used for AAD prevention. Materials and Methods: In this prospective, randomized, double-blind, placebo-controlled, single-center study, we enrolled 156 children aged between 1 and 18 years, treated with antibiotic due to acute respiratory or urinary tract infection. We randomly allocated children 1:1 to receive 100 mg of bLf or a placebo twice a day orally for the whole period of antibiotic therapy. The primary outcome was the occurrence of antibiotic-associated diarrhea during and up to 2 weeks after antibiotic therapy. The secondary endpoint was intravenous rehydration or antibiotic withdrawal due to diarrhea. We performed intention-to-treat analysis. Results: We included 150 patients in intention-to-treat analysis. AAD occurred in 16 of 75 (21.3%) patients in bLf group and in 7 of 75 (9.3%) individuals in placebo group [OR = 2.6, (95% CI: 1.01–6.84), p = 0.04]. Relative risk was 2.29 (95% CI: 0.89–5.88). The need for intravenous rehydration occurred in one patient in the placebo group ( p = 0.3). We observed no adverse effects in neither of the groups. Discussion: The trial indicated that bLf is not effective in AAD prevention. The risk for AAD was higher in bovine lactoferrin group as compared with placebo. We registered the study protocol on ClinicalTrials.gov ( {"type":"clinical-trial","attrs":{"text":"NCT02626104","term_id":"NCT02626104"}} NCT02626104 ).

【 授权许可】

CC BY